Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
5
Not yet recruiting, industry sponsors, Hematology and blood cancers, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed194
5 trials
Showing 1 to 5, recently updated first.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyDaiichi Sankyo (DSNKY)
NCT07949344 · 40 participants (planned) · Start Dec 1, 2026 · Primary completion Jun 30, 2030
Drug: Quizartinib; Chemotherapy · For: Acute Myeloid Leukemia
- A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS)Pivotal-lookingNot yet recruiting
Geron CorporationIndustry
NCT07939451 · 100 participants (planned) · Start Mar 2027 · Primary completion Jul 2030
Drug: Imetelstat (7.1 mg/kg); Imetelstat (3.55 mg/kg) · For: MDS (Myelodysplastic Syndrome); MDS
PfizerPfizer (PFE)
NCT07881835 · 75 participants (planned) · Start Oct 22, 2026 · Primary completion Feb 16, 2029
Drug: Elranatamab · For: Relapsed/Refractory Multiple Myeloma; Multiple Myeloma
- Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD PatientsPivotal-lookingNot yet recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07079579 · 120 participants (planned) · Start Aug 2025 · Primary completion Jun 2027
Drug: Enarodustat 2mg; Enarodustat 3mg and 1 more · For: Renal Anemia in Non-dialysis Chronic Kidney Disease
Sites: Beijing, China
- A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05367765 · 2,400 participants (planned) · Start Apr 30, 2022 · Primary completion Apr 30, 2027
Drug: Flumatinib; Imatinib · For: CML, Chronic Phase
Sites: Harbin, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.